References
- Parish SJ, Gillespie JA. The evolving role of oral hormonal therapies and review of conjugated estrogens/bazedoxifene for the management of menopausal symptoms. Postgrad Med. 2017;129(3):340–351.
- Blümel JE, Arteaga E, Parra J, et al. Decision-making for the treatment of climacteric symptoms using the Menopause Rating Scale. Maturitas. 2018;111:15–19.
- Menopause Rating Scale (MRS). Languages. Available from: http://www.menopause-rating-scale.info/languages.htm
- Schneider HP, Heinemann LA, Rosemeier HP, et al. The Menopause Rating Scale (MRS): reliability of scores of menopausal complaints. Climacteric. 2000;3(1):59–64.
- Heinemann LA, DoMinh T, Strelow F, et al. The Menopause Rating Scale (MRS) as outcome measure for hormone treatment? A validation study. Health Qual Life Outcomes. 2004;2(1):67.
- Dinger J, Zimmermann T, Heinemann LA, et al. Quality of life and hormone use: new validation results of MRS scale. Health Qual Life Outcomes. 2006;4(1):32.
- Mendoza N, Hernández C, Cornellana MJ, et al. Factors determining the use of hormonal therapy and phytotherapy in Spanish postmenopausal women. Climacteric. 2016;19(4):375–380.
- Parazzini F. Trends of determinants of hormone therapy use in Italian women attending menopause clinics, 1997–2003. Menopause. 2008;15(1):164–170.
- Amigoni S, Morelli P, Chatenoud L, et al. Cross-sectional study of determinants of menopausal age and hormone replacement therapy use in Italian women. Climacteric. 2000;3(1):25–32.
- Fagulha T, Gonçalves B, Ferreira A. A population-based assessment of midlife Portuguese women's experience of perimenopause and menopause. Health Care Women Int. 2011;32(7):559–580.
- Harlow SD, Gass M, Hall JE, et al. Executive summary of the Stages of Reproductive Aging Workshop +10: addressing the unfinished agenda of staging reproductive aging. Climacteric. 2012;15(2):105–114.
- Gazibara T, Dotlic J, Kovacevic N, et al. Validation of the Menopause Rating Scale in Serbian language. Arch Gynecol Obstet. 2015;292(6):1379–1386.
- Beck AT, Steer RA, Ball R, et al. Comparison of Beck Depression Inventories -IA and -II in psychiatric outpatients. J Pers Assess. 1996;67(3):588–597.
- Novovic Z, Mihic L, Tovilovic S, et al. Psychometric characteristics of the Beck depression inventory on a Serbian student sample. Psihologija. 2011;44(3):225–243.
- Pekmezovic T, Popovic A, Tepavcevic DK, et al. Factors associated with health-related quality of life among Belgrade university students. Qual Life Res. 2011;20(3):391–397.
- Gordon JL, Rubinow DR, Eisenlohr-Moul TA, et al. Efficacy of transdermal estradiol and micronized progesterone in the prevention of depressive symptoms in the menopause Transition A randomized clinical trial. JAMA Psychiatry. 2018;75(2):149–157.
- Strothmann A, Schneider HP. Hormone therapy: the European women's perspective. Climacteric. 2003;6(4):337–346.
- Lindh-Åstrand L, Hoffmann M, Hammar M, et al. Hot flushes, hormone therapy and alternative treatments: 30 years of experience from Sweden. Climacteric. 2015;18(1):53–62.
- Donati S, Satolli R, Colombo C, et al. Informing women on menopause and hormone therapy: Know The Menopause a multidisciplinary project involving local healthcare system. PLoS One. 2013;8(12):e85121.
- Al-Safi ZA, Santoro N. Menopausal hormone therapy and menopausal symptoms. Fertil Steril. 2014;101(4):905–915.
- Rossouw JE, Anderson GL, Prentice RL, et al. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321–333.
- Simpson EE. Predictors of intentions to use hormone replacement therapy in clinical postmenopausal women. Climacteric. 2012;15(2):173–180.
- Legare F, Godin G, Guilbert E, et al. Determinants of the intention to adopt hormone replacement therapy among premenopausal women. Maturitas. 2000;34(3):211–218.